Anika signals 1%-9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations
Source: SeekingAlpha
2026-02-26 13:58:48 ET
More on Anika Therapeutics
- Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
- Anika Therapeutics Non-GAAP EPS of $0.31 beats by $0.29, revenue of $30.6M beats by $1.72M
- Anika Therapeutics appoints Stephen Griffin as CEO
- Seeking Alpha’s Quant Rating on Anika Therapeutics
- Historical earnings data for Anika Therapeutics
Read the full article on Seeking Alpha
For further details see:
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations
Anika Therapeutics Inc.
NASDAQ: ANIK
ANIK Trading
4.56% G/L:
$14.46 Last:
39,990 Volume:
$14.09 Open:
ANIK Latest News
February 18, 2026 04:01:00 pm
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
February 12, 2026 04:01:00 pm
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
ANIK Stock Data
$150,557,526
10,879,368
2.15%
33
N/A
Medical Equipment & Supplies
Healthcare
US
Bedford
